Autopsy report · NCT00448539

Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

“The study was terminated early by the sponsor due to the discontinuation of clinical development for rufinamide.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 2 months before it stopped.
• 286 participants enrolled.
• Results were posted on the registry 2 years 7 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Eisai Inc.

Sponsor type

Industry

Conditions

Refractory Partial Onset Seizures

Interventions

Rufinamide

Participants

286

Sites

27

Countries

United States

Trials that died the same way

• A Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC)
  “The study was terminated by sponsor for reasons of adjusted clinical development strategy.” (65% match in meaning)
• Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
  “This study was terminated early due to the Sponsor's decision to discontinue development of the investigational drug and close the program.” (65% match in meaning)
• Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell Carcinoma
  “The study was terminated voluntarily by the sponsor due to changes in clinical development strategy.” (63% match in meaning)
• Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers
  “The study was terminated due to the sponsor's decision to discontinue the clinical trial.” (63% match in meaning)
• A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older
  “The study was terminated early by the sponsor due to strategic reprioritization reasons.” (62% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.